What does Wegovy do for cardiovascular health?

Which cardiovascular events does Wegovy's licence actually cover?

The UK licence for semaglutide 2.4mg (Wegovy) in the cardiovascular setting covers reduction of major adverse cardiovascular events (specifically non-fatal heart attack, non-fatal stroke, and death from cardiovascular causes) in adults who already have established cardiovascular disease and a body mass index of 30 or higher. This is a separate authorisation from the weight-management licence, and it matters clinically because the two indications can coexist in the same patient. A prescriber working through someone's history would consider both together.

It is worth being precise about what the licence does not include. It is not a licence for general heart-health improvement or cholesterol reduction as a primary target, and it does not cover people who have cardiovascular risk factors alone, without established disease. The detailed breakdown of semaglutide's cardiovascular benefits sets out the boundaries of the evidence clearly. As with all uses of Wegovy, this remains a prescription-only medicine requiring clinical assessment.

The MHRA approved the cardiovascular indication on the strength of a single large outcome trial, SELECT, rather than a body of smaller studies. That design choice gives the evidence a particular weight, regulators treat purpose-built cardiovascular outcome trials as the gold standard for this kind of claim. NHS guidance on semaglutide reflects the dual-indication status of the medicine.

What did the SELECT trial actually find?

SELECT enrolled 17,604 adults aged 45 or over who had pre-existing cardiovascular disease, a BMI of at least 27, but no diabetes, that last point made it unusual. Most cardiovascular outcome trials for this class of medicines were conducted in people with type 2 diabetes. SELECT was designed specifically to test whether the benefit extended to people without it.

Over roughly five years of follow-up, participants receiving semaglutide 2.4mg weekly had a 20% lower rate of major adverse cardiovascular events compared with those receiving placebo. Both groups received standard care alongside the study drug. In absolute terms, that translated to 6.5% of the semaglutide group experiencing a primary event versus 8.0% in the placebo group.

One finding that drew particular attention from cardiologists: the separation in the survival curves began early, before the weight trajectories of the two groups had diverged substantially. That timing suggested some cardiovascular effects were not simply downstream of losing body fat. Researchers have proposed direct anti-inflammatory effects and improvements in blood-pressure and lipid profiles as possible contributors, and those who want to understand the different ways semaglutide can be delivered may find it useful to read about semaglutide intramuscular administration as one option within that broader picture, though the mechanisms remain an active area of investigation. The page on how Wegovy helps cardiovascular health goes into the proposed mechanisms in more detail.

Does this mean Wegovy is a heart medicine rather than a weight-loss one?

In practice, the two are not in competition. The same weekly pen can address both indications simultaneously for someone who qualifies on both grounds, and many people with established cardiovascular disease also carry significant weight. Clinicians treating that overlap now have a medicine with outcome data rather than surrogate-marker data alone.

That said, it is easy to over-read the trial. SELECT studied a specific group: people already living with heart disease, without diabetes, with a BMI above 27. It does not tell us what happens in people with heart-disease risk factors rather than established disease, or in people with diabetes, or at lower BMI thresholds. Extrapolating beyond the trial population is something prescribers are rightly cautious about.

Semaglutide also holds a newer UK authorisation (conditional approval from July 2026 for a form of fatty liver disease called MASH) which illustrates how the drug's profile is evolving beyond weight management. The cardiovascular indication, though, remains the most clinically significant non-weight outcome to date. If you are thinking about whether any of this is relevant to your situation, our prescribers are available to talk it through. You might also find it helpful to look at the wider treatment options available through a clinician-led service.

How does the cardiovascular licence interact with who can access Wegovy privately in the UK?

The SELECT trial's BMI entry threshold was 27, meaning people below 30 with established cardiovascular disease were included. The licensed indication for cardiovascular risk reduction reflects that: adults with established heart disease and a BMI of at least 27 may be eligible on cardiovascular grounds, even if they would not meet the weight-management BMI criteria of 30 or above.

In practice, a prescriber at a regulated pharmacy considers each application in full. Someone presenting with a history of heart attack and a BMI of 28 sits in a different clinical position than someone presenting for weight management alone. Every case is assessed individually; there is no single threshold that automatically opens or closes the door.

For a realistic sense of what private treatment costs and what is included in a regulated service, the guide to Wegovy pricing in the UK is a sensible starting point. The short version: a prescription-only medicine dispensed via a GPhC-registered pharmacy should always come with clinical oversight built in, and the price should reflect that. nume's GPhC registration is publicly verifiable at the pharmacy register.

If the cardiovascular indication is relevant to your medical history, the most useful next step is a consultation. A clinician who has seen your full picture, not a summary of a trial abstract, is the right person to advise you. Speak to our prescribers to get that conversation started.